Дисертації з теми "Vaccine candidate protein"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-44 дисертацій для дослідження на тему "Vaccine candidate protein".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Sikora, Christopher A., and University of Lethbridge Faculty of Arts and Science. "Identification of a vaccine candidate in protein extracts from francisella tularensis." Thesis, Lethbridge, AB : University of Lethbridge, Faculty of Arts and Science, 2003, 2003. http://hdl.handle.net/10133/235.
Повний текст джерелаxii, 97 leaves ; 29 cm.
Koivula, Therese. "Production and characterisation of a chlamydial antigen candidate for vaccine trials." Thesis, Uppsala universitet, Molekylär biomimetik, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-451976.
Повний текст джерелаKreida, Stefan. "Chimeric MOMP : Expression of a Chlamydia Vaccine Candidate in Arabidopsis thaliana and Escherichia coli." Thesis, Örebro universitet, Akademin för naturvetenskap och teknik, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-20113.
Повний текст джерелаWright, Judith Claire. "Studies on the porB gene of Neisseria meningitidis : use as an epidemiological marker and as a potential vaccine candidate." Thesis, University of Southampton, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.323956.
Повний текст джерелаGuevara-Patino, Jose Alejandro. "Antibody responses to and the structure of plasmodium falciparum merozoite surface protein-1 : a candidate malaria vaccine antigen." Thesis, University College London (University of London), 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.300163.
Повний текст джерелаGonzález, Zabala Juliana. "Conserved hemagglutinin peptides of influenza virus as potential multivalent vaccine candidate: characterization of immune response in different animal models." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/384602.
Повний текст джерелаInfluenza A viruses (IAVs) are responsible for pandemic outbreaks of influenza, and for most of the well-known annual flu epidemics, in humans, poultry and pigs. IAVs are divided into subtypes, based on the nature of their surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). The HA is a homotrimeric surface glycoprotein that mediates influenza viral entry via cellular attachment and membrane fusion events. The receptor-binding pocket of HA is surrounded by antigenically variable antibody binding sites. Therefore, antibodies bounded to these sites should, in principle, block the binding to receptor proteins, inhibiting viral entry, demonstrating hemagglutinin inhibition activity and viral neutralization activity. However, the subunit 1 of HA (HA1) is highly variable across viruses and tends to change under immune pressure and, hence, easily evades the neutralizing antibodies induced by previous vaccinations or infections. The negative implications of influenza virus infections push the world to promote the development of multivalent flu vaccines that protect against all human influenza strains. Therefore, the field of bioinformatics has become a major part of the identification and early validation of new therapeutic targets and could be an essential first step in the development of an effective vaccine for influenza virus that represents the high variability of its antigenic determinants. Therefore, in this thesis it was postulated that the HA1 could represent a potential target for a multivalent vaccine of influenza infection. Consequently, the general objective of this thesis was to select conserved peptides from the HA1 of influenza viruses and to evaluate the efficacy of the selected candidates to induce immunity that can protect animal against infection. To achieve this objective, three studies were undertaken in mice (Chapter 1), pigs (chapter 2) and chickens (Chapter 3). In the first study, we evaluated the protective effect of improved HA1-peptides against the pandemic H1N1 2009 virus and a H7N1 highly pathogenic influenza virus (HPAIV) in a mouse model (Chapter 1). In this study, mice were intraperitoneally vaccinated with the peptide mix (NG34+DC89), and next challenged with either the pH1N1 or the H7N1 strain of Influenza virus. Conversely to the 85% mortality observed in control mice, independently of the virus used for challenge, 80% and 66% of the peptide-vaccinated mice survived the challenge with pH1N1 and H7N1, respectively, without detection of influenza viruses (IV). Vaccinated mice surviving correlated with the presence of cross-reactive neutralizing antibodies in sera prior to challenge. The immunization with NG34+DC89 also induced mucosal immune responses demonstrated with the presence of IgA in bronchoalveolar lavage in 50% of the animals. Our results also show that NG34+DC89 is capable to induce cross-neutralizing antibodies and protection against two heterologous IV, pH1N1 and H7N1. Thus, NG34+DC89 represent an attractive immunogen, which could be further optimized for future multivalent vaccine formulations against influenza virus. In the second study, we tested the immunogenicity of a HA1-peptide cocktail in a pig model to assess whether this new formulation can confer immunity to a wide range of IAVs in vitro (Chapter 2). Four peptides (NG34, DC55, RA22 and SS35) within the HA1 from H1 viruses were selected, and evaluated their immunogenicity in conventional farm pigs against homologous and heterologous viruses of influenza. Peptides immunizations induced HA neutralizing and inhibiting antibodies against homologous viruses. Those also cross-reacted against heterologous viruses like H7N1 and H5N2 and, most importantly, the circulating H3N2. Moreover, secretory IgA-specific HA antibodies in nasal swabs were detected. Altogether, the results show that the peptides tested were immunogenic in pigs. The humoral response with hemagglutinin-inhibiting and cross-neutralizing activity generated after immunization could be used in further studies of protective heterosubtypic immunity. In the third study we evaluated the protective effect of improved HA1-peptides against H7N1 highly pathogenic influenza virus (HPAIV) in chickens, a natural host model (Chapter 3). In this study, based on ISM, we selected two highly conserved peptides (NG34 and SS35) of a H1 influenza virus strain and used them to vaccinate free-range chickens. The vaccination with both NG34 and SS35 peptides induced specific antibodies that recognized heterologous viruses, as H7N1 HPAIV and H5N2 Low pathogenic avian virus (LPAIV) in vitro. Vaccination with NG34 peptide elicited a protective antibody response that conferred partial protection against a lethal challenge with H7N1 HPAIV. Furthermore, NG34 peptide induced a mucosal immune response, which correlated with reduced viral shedding in oropharyngeal/cloacal swabs and feather pulp. On the contrary, SS35 peptide vaccinated animals failed to produce an efficient protective immune response as no survival against lethal H7N1 challenge was achieved. Finally, it remains to point out that all HA1-peptides from H1 subtype of influenza virus were selected by the method of informative spectra (ISM). Four main general conclusions can be drawn from these studies: (i) HA1-peptides are immunogenic in all the animals models tested (mice, pigs and chickens) and induce humoral and mucosal immune response. (ii) Novel conserved immunogenic peptides from the hemagglutinin subunit 1 protein of influenza viruses confer partial protection against different viral subtypes in mice; (iii) Pigs vaccinated with HA1 peptides elicit neutralizing and hemagglutination-inhibiting antibody responses against different subtypes of Influenza A virus and (iv) Synthetic peptides from the hemagglutinin of influenza viruses confer partial protection against highly pathogenic A/H7N1 virus in a free-range chicken model. Overall, these data provide insights on new approaches for vaccination in influenza and understanding of the immune response against influenza viruses in mice, pigs and chickens.
Tawfick, Abd Raboh Mahmoud Mohamed. "Characterisation of the Salmonella Stk fimbrial operon and examination of Stkf, the putative adhesion protein, as a potential diagnostic and vaccine candidate." Thesis, University of Leicester, 2012. http://hdl.handle.net/2381/11004.
Повний текст джерелаEgan, Andrea. "Human immune responses to the C-terminus of the malaria vaccine candidate antigen, the major merozoite surface protein of Plasmodium falciparum (PfMSP1)." Thesis, University of Edinburgh, 1995. http://hdl.handle.net/1842/13778.
Повний текст джерелаJäschke, Anja [Verfasser], and Michael [Akademischer Betreuer] Lanzer. "Analysis of the human immune response against the Merozoite Surface Protein (MSP)-1 from Plasmodium falciparum – a malaria vaccine candidate / Anja Jäschke ; Betreuer: Michael Lanzer." Heidelberg : Universitätsbibliothek Heidelberg, 2017. http://d-nb.info/1178010619/34.
Повний текст джерелаMacLean, James Malcolm. "Investigation of the use of recombinant BCG, expressing the major capsid protein (LI) of human papillomavirus type 16, as a candidate vaccine for cervical cancer." Doctoral thesis, University of Cape Town, 2005. http://hdl.handle.net/11427/2730.
Повний текст джерелаMiller, John Paul. "Picornaviruses as candidate vaccine vectors expression of HIV-1 antigens and examination of the effect of HPeV-1 viral 2BC protein on surface MHC-1 expression /." Diss., Restricted to subscribing institutions, 2009. http://proquest.umi.com/pqdweb?did=1872073641&sid=1&Fmt=2&clientId=1564&RQT=309&VName=PQD.
Повний текст джерелаHerr, Roger Alan. "Evaluation of Coccidioides posadasii antigens as recombinantly expressed monovalent, divalent, and chimeric vaccine candidates." Connect to full-text via OhioLINK ETD Center, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=mco1160404292.
Повний текст джерела"In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Medical Sciences." Major advisor: Garry Cole. Includes abstract. Document formatted into pages: ii, 206 p. Title from title page of PDF document. Title at ETD Web site: Evaluation of two homologous Coccidioides posadasii antigens as recombinantly expressed monovalent, divalent, and chimeric vaccine candidates. Bibliography: pages 75-83, 116-120, 165-169, 185-204.
Rohrbough, James Gary Jr. "Identification of Protein Vaccine Candidates Using Comprehensive Proteomic Analysis Strategies." Diss., The University of Arizona, 2007. http://hdl.handle.net/10150/194491.
Повний текст джерелаDhanasarnsombut, Kelwalin. "Unstructured proteins of the malaria parasite Plasmodium falciparum as vaccine candidates." Thesis, University of Edinburgh, 2013. http://hdl.handle.net/1842/8034.
Повний текст джерелаLewis, Susan. "The feasibility of Opa proteins as vaccine candidates against Neisseria miningitidis." Thesis, University of Oxford, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.547606.
Повний текст джерелаTsolakos, Nikolaos. "Identification and characterisation of vaccine candidate proteins in the Neisseria meningitidis surface proteome." Thesis, Imperial College London, 2011. http://hdl.handle.net/10044/1/9156.
Повний текст джерелаCarre, Heather Emily. "Expression and analysis of recombinant mycoplasma hyponeumoniae proteins as potential subunit vaccine candidates." Thesis, Royal Veterinary College (University of London), 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.522182.
Повний текст джерелаLoureiro, Silvia. "Recombinant haemagglutinin-Fc fusion proteins expressed in insect cells as candidate influenza vaccines." Thesis, University of Reading, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.553691.
Повний текст джерелаKreutzfeld, Oriana. "Pre-clinical evaluation and improvement of attenuated malaria sporozoite vaccine candidates." Doctoral thesis, Humboldt-Universität zu Berlin, 2020. http://dx.doi.org/10.18452/20968.
Повний текст джерелаMalaria vaccine candidates providing both safety and efficacy against pre-erythrocytic stages remain largely elusive. Experimental immunizations with live genetically attenuated parasites (GAPs) preventing the development beyond the clinically silent liver stage have proven safe and efficacious. GAP vaccine candidate ΔSLARP, provides the most robust life cycle arrest, however, immunizations do not elicit long-lasting immunity. In contrast, ΔP36p/P36 sporozoites elicit long-lasting immunity, but lead to breakthrough infections during immunizations. This study gives a systematic pre-clinical evaluation of a triple knockout (tKO) GAP by combining ΔSLARP and ΔP36p/P36. Complete arrest of tKO parasites in cultured hepatoma cells and sporozoite-infected mice was confirmed, but time to blood infection after a sporozoite challenge revealed reduced efficacy of the tKO vaccine. While superior immunity can be achieved by a late developmental arrest at liver-to-blood stage conversion, the underlying molecular mechanisms remain elusive. An important question is whether parasite antigens are exposed to the hepatocyte cytoplasm. Protein translocation into the host cell cytoplasm mediated by PTEX, a protein translocon, is absent during liver stage maturation as a core component of PTEX, Heat-shock-protein 101 (HSP101), is not expressed. To clarify the role of HSP101 in liver stage protein export transgenic HSP101 expressing Plasmodium berghei parasites were generated. Parasites expressing elevated levels of HSP101 show severe liver stage growth defects in vitro and in vivo, lack early liver stage export and inferior protection in immunized animals. Our results suggest that HSP101 expression is tightly controlled and PTEX dependent early liver stage export cannot be restored solely by HSP101 overexpression. Overall, pre-clinical analysis and improvement of GAP-based vaccine candidates can inform on-going human vaccine trials and boost malaria vaccine development.
Larocque, Renée 1975. "Giardia CWP2 : determining its immunogenic[i]ty and its potential as a candidate for vaccine against giardiasis." Thesis, McGill University, 2000. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=30683.
Повний текст джерелаShaw, H. Alexandra. "The dynamic surface of C. difficile : understanding surface proteins and their potential as vaccine candidates." Thesis, Imperial College London, 2013. http://hdl.handle.net/10044/1/12875.
Повний текст джерелаAmoudy, Hanady Abdelrahim. "Identification of M. tuberculosis-specific proteins as candidate antigens for diagnostic tests and an improved BCG vaccine." Thesis, Imperial College London, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.392490.
Повний текст джерелаHashimoto, Vivian Lika. "Clonagem e expressão gênica de antígenos candidatos vacinais contra leptospirose." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-11062012-082558/.
Повний текст джерелаLeptospirosis is an infectious disease that affects domestic animals, wildlife and humans, caused by bacteria of the genus Leptospira. In Brazil, pulmonary hemorrhage is the major risk factor to death with mortality rates for this form of the disease over than 50%. Thus, the development of a preventive vaccine and better understanding of injury mechanisms involved in leptospirosis would allow us to propose new therapies to reduce the high mortality associated with the disease. In the present study we proposed to investigate twelve genes of Leptospira interrogans serovar Copenhageni. The identification of one protease opens the way for the investigation of a possible protease involved in bleeding processes in this important zoonosis. With the results presented here, we expect to contribute to the biology and pathogenicity characterization of leptospirosis.
Zhang, Yu. "Rational design of human metapneumovirus live attenuated vaccine candidates by inhibiting viral messenger RNA cap methyltransferase." The Ohio State University, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=osu1388027781.
Повний текст джерелаTeixeira, Aline Rodrigues Florencio. "Avaliação e caracterização de candidatos vacinais voltados para o controle da leptospirose." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-25082016-100745/.
Повний текст джерелаLeptospirosis is a systemic disease caused by pathogenic bacteria of genus Leptospira. The development of new strategies to prevent the disease is needed. Vaccines emerge as strong candidates to fight the problem.Currently research has focused to identify conserved antigens This project selected three hypothetical proteins of L. interrogans. Thesecoding sequences were characterized for their possible role in pathogenesis and their potential to protect animals against challenge with virulent leptospires. Genes were amplified by PCR and cloned into the expression vector pAE. The recombinant proteins were purified by metal affinity chromatography and were recognized by confirmed human leptospirosis serum samples.LIC13479 and LIC10050 proteins were able to bind with laminin, plasminogen and plasma fibronectin. The coding sequence LIC10537 was cloned in two fragments. Fragment 2was able to interact with plasminogen. All proteins were able to generate active plasmin. The recombinant proteins were able of inducing an immune response. Evaluation of immunoprotection in leptospirosis hamster model followed by challenge with virulent bacteria showed that the recombinant proteins conferred partial protection.
Panethymitaki, Chrysoula. "Structure-function studies of kinetoplastid myristoylCoA : protein N-myristoyltransferase and two substrates, the 'Leishmania' vaccine antigen candidates, HASPA and HASPB." Thesis, Imperial College London, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.413682.
Повний текст джерелаMendes, Jéssica Mariane Ferreira. "Produção e Avaliação de antígenos recombinantes candidatos a componente de uma vacina contra leishmaniose visceral canina." reponame:Repositório Institucional da FIOCRUZ, 2016. https://www.arca.fiocruz.br/handle/icict/14161.
Повний текст джерелаApproved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-05-10T16:21:54Z (GMT) No. of bitstreams: 1 Jessica Mariane Ferreira Mendes Produção... 2016.pdf: 1965926 bytes, checksum: ac5119592b97390470f4914f6fcbddf0 (MD5)
Made available in DSpace on 2016-05-10T16:21:54Z (GMT). No. of bitstreams: 1 Jessica Mariane Ferreira Mendes Produção... 2016.pdf: 1965926 bytes, checksum: ac5119592b97390470f4914f6fcbddf0 (MD5) Previous issue date: 2016
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Uma vacina efetiva contra a leishmaniose visceral (LV) canina pode contribuir para o controle da doença no homem. Visando o desenvolvimento de uma vacina contra LV canina, antígenos recombinantes de L. infantum foram selecionados em nosso laboratório pelo uso de uma mistura de soros de seres humanos ou cães naturalmente infectados pela L. infantum. Alguns destes antígenos foram testados em diversos protocolos de imunização, incluindo uso de diferentes adjuvantes, em camundongos ou cães. A imunização de camundongos ou cães com um dos antígenos recombinantes (rLci2B) usado isoladamente ou em associação com saponina induziu resposta imune Th2 ou Th1/Th2, respectivamente, não protetoras contra a infecção experimental. Com a determinação da sequência deduzida de aminoácidos notou-se que a maioria dos antígenos selecionados apresenta um segmento com sequência de aminoácidos única (domínio não repetitivo) e segmentos com sequência de aminoácidos com motivos repetitivos (domínios repetitivos). Possivelmente a incapacidade dos antígenos recombinantes de induzir uma resposta imune predominantemente Th1, protetora contra a LV, seria por conta da presença de domínios repetitivos, que favorecem a apresentação antigênica por linfócitos B e, consequentemente, estimulam uma resposta imune Th2. Para avaliar o direcionamento da resposta imune pelos dois tipos de domínio, novas construções de DNA foram concebidas de modo a codificar apenas domínio(s) não repetitivo(s) ou domínio(s) não repetitivo(s) e domínios repetitivos. OBJETIVOS: Produzir quatro proteínas recombinantes com domínios não repetitivos (rLci2-NT-CT, rLci3-NT-CT, rLci10-NT e rLci12-NT-CT) e avaliar a capacidade desses polipeptídios de induzir resposta imune celular in vitro em cães assintomáticos inoculados por via dérmica com L. infantum. MATERIAIS E MÉTODOS: Foram realizadas: a) a subclonagem de construções de DNA (Lci3-NT-CT, Lci10-NT e Lci12- NT-CT) em um plasmídeo apropriado para expressão em Escherichia coli, b) a determinação de condições apropriadas para produção das proteínas recombinantes (rLci2-NT-5R-CT, rLci2-NT-CT, rLci3-NT-2R-CT, rLci3-NT-CT, rLci10-NT-2R e rLci10- NT) c) a purificação das proteínas recombinantes por cromatografia de afinidade e d) avaliação da capacidade dos polipeptídios de induzir estimulação de células mononucleares sangue periférico (PBMC) de cães assintomáticos inoculados por via dérmica com L. infantum. RESULTADOS: Três (rLci2-NT-CT, rLci2-NT-5R-CT, rLci3- NT-CT, rLci3-NT-2R-CT, rLci10-NT e rLci10-NT-2R) dos quatro pares de polipeptídios recombinantes foram expressos, produzidos e purificados. Três antígenos recombinantes (rLci2-NT-5R-CT, rLci2-NT-CT e rLci3-NT-2R-CT) promoveram a linfoproliferação in vitro utilizando PBMC de cães assintomáticos inoculados por via dérmica com L. infantum CONCLUSÕES: Três das seis proteínas produzidas induziram a linfoproliferação, sendo a maior linfoproliferação encontrada para PBMC estimulado com a proteína sem domínios repetitivos (rLci2-NT-CT). Avaliações adicionais são necessárias para comprovar a utilidade destas moléculas em formulação de vacina contra leishmaniose visceral canina.
An effective vaccine against visceral leishmaniasis (VL) dog can help to control the disease in man. Aiming at development of a vaccine against canine VL, recombinant antigens of L. infantum were selected in our laboratory by using a mixture of sera from humans or dogs naturally infected with L. infantum. Some of these antigens were tested in different immunization protocols, including use of different adjuvants in mice or dogs. The immunization of mice or dogs with a recombinant antigens (rLci2B) used alone or in combination with saponin induced Th2 response or Th1 / Th2, respectively, did not protective against experimental infection. With the determination of the deduced amino acid sequence it was noted that most of the antigens selected segment has a unique amino acid sequence (non-repetitive domain) and segments of amino acid sequence with repetitive motifs (repetitive domains). Possibly the inability of recombinant antigens to induce an immune response predominantly Th1 protective against LV would be due to the presence of repetitive domains that promote antigen presentation by B cells and thus stimulate an immune response Th2. To assess the direction of the immune response by two types of domain, new DNA constructs were designed to encode only the domain (s) not repetitive (s) or domain (s) not repetitive (s) and repetitive fields. MATERIALS AND METHODS: Were performed: a) subcloning DNA constructs (rLci3-NT-CT, rLci10-NT and rLci12-NT-CT) into a suitable plasmid for expression in Escherichia coli, b) determining the appropriate conditions for the production of proteins recombinant (rLci2- NT-5R-CT, rLci2-NT-CT, rLci3-NT-2R-CT, rLci3-NT-CT, rLci10-NT-2R and rLci10-NT) c) purification of recombinant proteins by chromatography affinity d) evaluating the ability of polypeptides rLci2-NT-CT, rLci3-NT-CT and rLci10-NT to induce stimulation of peripheral blood mononuclear cells (PBMC) from healthy dogs inoculated dermal with L. infantum. RESULTS: Three (rLci2-NT-CT, rLci2-NT-5R-CT, rLci3-NT-CT, rLci3-NT-2R-CT, rLci10- NT and rLci10-NT-2R) of the four pairs of recombinant polypeptides are expressed, produced and purified. Three recombinant antigens (rLci2-NT-5R-CT, rLci2-NT-CT and rLci3-NT-2R-CT) promoted lymphocyte proliferation in vitro using asymptomatic dogs PBMC inoculated dermal L. infantum CONCLUSIONS: Three of the six proteins produced induced lymphoproliferation, most lymphoproliferation was found to PBMC stimulated with the protein without repetitive domains (rLci2-NT-CT). Additional evaluations are necessary to confirm the utility of these molecules against canine visceral leishmaniasis vaccine formulation
Fernandes, Rafaela Sachetto. "Caracterização molecular de proteínas secretadas da família VAL (Venon Allergen-Like Protein) de Schistosoma mansoni e avaliação como antígenos vacinais." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-24082016-102604/.
Повний текст джерелаSchistosomiasis is a disease caused by trematodes of the genus Schistosoma. Among the genes identified in the parasite transcriptome, members of SmVAL (Schistosoma mansoni Venom Allergen-Like) gene family were proposed as vaccine candidates. SmVALs were identified in cercariae and schistosomule secretions in vitro, the SmVAL4 and 24 transcripts were located to the germ ball acetabular glands and SmVAL4 native protein was identified in cercariae extract, indicating functions in skin penetration. On the other hand, SmVAL13 and 14 transcripts were located to the anterior esophageal gland of adult worms, suggesting roles in the blood feeding processes. Immunization with rSmVAL4, 6, 7, 13, 14 and 18 proteins co-administered did not protected mice against experimental challenge, however, there was a decrease in the number of females and the number of eggs in the immunized group. The investigation of functions for secreted proteins showed that rSmVAL18 interacts with plasminogen in vitro thus favoring the host invasion.
Shaan, Lakshmanappa Yashavanth. "Development and Evaluation of Efficacy of Novel Porcine Reproductive and Respiratory Syndrome (PRRS) Virus Vaccine Candidates in Pigs." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1532064253191032.
Повний текст джерелаMoreno, Adriana Tonet. "Avaliação da variabilidade do candidato vacinal PspC (Pneumococcal surface protein C) em isolados de Streptococcus pneumoniae do Hospital Universitário da Universidade de São Paulo." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-102932/.
Повний текст джерелаStreptococcus pneumoniae is the causative agent of several diseases, such as meningitis and pneumonia. PspC (Pneumococcal surface protein C) has been described as an important vaccine candidate protein as it could provide wide coverage with low cost of production. PspC is a virulence factor capable of binding to Factor H (FH) and secretory IgA (sIgA). PspC is polymorphic antigen, and therefore it is crucial to evaluate its variability. In the present work we have determined the PspC group of 13 pneumococcal isolates obtained at the University Hospital of the University of São Paulo. Antisera against different PspC groups were produced and PspC group 3 (PspC3) was able to induce antibodies that recognized different groups of PspC. Antibodies to PspC3 reduced binding of FH and sIgA to pneumococcus in in vitro assays. However, no protection was observed against a murine model of nasopharyngeal colonization by immunization with PspC3. This was possibly due to deficiencies in the experimental model.
Pannaraj, Pia S. Baker Carol J. Aragaki Corinne Pedroza Claudia. "Alpha C protein of group B Streptococcus as a potential vaccine candidate." 2007. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:1451262.
Повний текст джерелаLe, TuQuynh Khac. "Assessing the immunogenicity of the major outer membrane protein porin B of Neisseria gonorrhoeae as a vaccine candidate." Thesis, 2014. https://hdl.handle.net/2144/14702.
Повний текст джерела"Expression, Purification, and Crystallization of CTB-MPR649-684, a Candidate Mucosal Vaccine Component Against HIV-1." Doctoral diss., 2015. http://hdl.handle.net/2286/R.I.29993.
Повний текст джерелаDissertation/Thesis
Doctoral Dissertation Biochemistry 2015
"The study on the 42kda carboxyl terminal fragment of plasmodium falciparum merozoite surface protein 1 (Pfmsp-1-42) and its processing fragments for candidate antigen of malarial vaccine." Thesis, 2007. http://library.cuhk.edu.hk/record=b6074345.
Повний текст джерелаNevertheless, following the breakthrough of expressing recombinant PfMSP-1 33 in our laboratory, we have demonstrated in this study that recombinant MSP-133 can elicit antibodies with a titer up to a million. Also, we observed that MSP-133 can help MSP-119 to induce protective immunity and such effect is independent from the covalent linkage between these two proteins. Most importantly, our results show that recombinant PfMSP-133 can elicit the production of antibodies that can potentiate the inhibitory effect of anti-MSP-142 serum at high serum dilution. Results of this study give new insights in malarial vaccine development in terms of optimizing the use of adjuvant and immunization regimens.
The 42kDa carboxyl terminal fragment of Plasmodium falciparum Merozoite Surface Protein-1 (PfMSP--142) is one of the most promising candidate antigens in the development of malarial vaccine. In vivo experiments in the 1990's showed that Aotus monkeys immunized with PfMSP--142 were protected from malarial challenge. Later on, other experiments also demonstrated the possibility of using recombinant PfMSP-142 as candidate antigen for malarial vaccine. Previously, recombinant PfMSP-142 (Bvp42) was expressed with the baculovirus expression system and characterized in our laboratory.
The aim of the first part of this project is to improve the production of Bvp42. Experimental results have shown that the expression level of Bvp42 was increased under a BMN compatible baculovirus expression vector---pVL1393. Besides, a codon optimized MSP-142 nucleotide is constructed for the construction of a baculovirus carrying codon optimized MSP-142 gene and aimed for higher expression level. Unfortunately, no Bvp42 expression is observed in the transfection samples and the reason of this observation is unclear. Meanwhile, the purification of Bvp42 was also improved. Pretreatment of the hemolymph with Q--sepharose before affinity chromatography could enhance the purity of the final product.
Yuen, Sai-hang Don.
"July 2007."
Adviser: Walter K. K. Ho.
Source: Dissertation Abstracts International, Volume: 69-01, Section: B, page: 0220.
Thesis (Ph.D.)--Chinese University of Hong Kong, 2007.
Includes bibliographical references (p. 183-195).
Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Abstracts in English and Chinese.
School code: 1307.
"B And T Cell Responses To Epitopes In Disulfide Bond-constrained Recombinant Pfs48/45 Protein, A Malaria Transmission-blocking Vaccine Candidate Antigen." Tulane University, 2015.
Знайти повний текст джерелаacase@tulane.edu
"Purification and characterization of a malaria vaccine candidate: Plasmodium falciparum merozoite surface protein-1 C-terminal processing fragment (MSP-142) expressed by baculovirus in silkworm larvae." 2003. http://library.cuhk.edu.hk/record=b5891679.
Повний текст джерелаOn t.p. "42" are subscripts following the word "MSP-1" in the title.
Thesis (M.Phil.)--Chinese University of Hong Kong, 2003.
Includes bibliographical references (leaves 117-125).
Abstracts in English and Chinese.
ACKNOWLEGEMENTS --- p.i
ABSTRACT --- p.ii
TABLE OF CONTENTS --- p.v
LIST OF FIGURE --- p.vii
LIST OF ABBREVIATIONS --- p.ix
CHAPTERS:
Chapter 1. --- BACKGROUND OF MALARIA
Chapter 1.1 --- Epidemilogy --- p.2
Chapter 1.2 --- Mode of Infection --- p.4
Chapter 1.3 --- Conventional Control & Vaccination --- p.9
Chapter 1.4 --- Vaccine Candidate PfMSV-142 --- p.16
Chapter 1.5 --- Cloning and Expression of pfMSP-142 --- p.26
Chapter 1.6 --- Aims of Study --- p.32
Chapter 2. --- Materials and Methods
Chapter 2.1 --- Materials --- p.32
Chapter 2.2 --- Methods --- p.38
Chapter 3. --- Construction of recombinants N-PfMSP-142 and C- PfMSP-142
Chapter 3.1 --- Construction of C-PfMSP-l42 --- p.51
Chapter 3.2 --- Construction ofN-PfMSP-l42 --- p.56
Chapter 4. --- Purification with IMAC
Chapter 4.1 --- Immobilized Metal Affinity Chromatography (IMAC) --- p.58
Chapter 4.2 --- Purification ofN-PfMSP-l42 --- p.61
Chapter 4.3 --- Purification profile of N-PfMSP-142 --- p.68
Chapter 4.4 --- Purification of C-PfMSP-l42 --- p.70
Chapter 4.5 --- Purification profile of C-PfMSP-142 --- p.73
Chapter 4.6 --- Expression pattern of recombinants PfMSP-142 --- p.76
Chapter 5. --- Purification combined with other chromatography method
Chapter 5.1 --- Affinity chromatography --- p.78
Chapter 5.2 --- Gel filtration chromatography --- p.80
Chapter 5.3 --- Ion exchange chromatography --- p.83
Chapter 5.4 --- Conclusion --- p.93
Chapter 6. --- Characteristic of IMAC products --- p.94
Chapter 7. --- Characteristic of N-hisPfMSP-l42 & C-hisPfMSP-l --- p.42
Chapter 7.1 --- Immunogenitcity of N-PfMSP-l42 and C-PfMSP-142 --- p.100
Chapter 7.2 --- Competitive ELISA --- p.105
Chapter 8. --- Discussion --- p.107
REFERENCE --- p.117
Werth, Eric P. "Evaluation of a potential Chylamydia psittaci vaccine candidate using recombinant vaccinia virus encoding the infection-specific C. psittaci GPIC proteins IncA and TroA." Thesis, 2001. http://hdl.handle.net/1957/28803.
Повний текст джерелаGraduation date: 2002
Locher, Christopher P. "Plasmodium falciparum merozoite surface and rhoptry proteins as malaria vaccine candidates." Thesis, 1992. http://hdl.handle.net/10125/9441.
Повний текст джерелаHsing-Chuan, Tsai. "Different Epitopes of EV71 Caspid Proteins, Other than VP1, become the Candidate of the EV71 Vaccine Development." 2006. http://www.cetd.com.tw/ec/thesisdetail.aspx?etdun=U0001-2707200610322400.
Повний текст джерелаTsai, Hsing-Chuan, and 蔡幸娟. "Different Epitopes of EV71 Caspid Proteins, Other than VP1, become the Candidate of the EV71 Vaccine Development." Thesis, 2006. http://ndltd.ncl.edu.tw/handle/28696632084440349433.
Повний текст джерела國立臺灣大學
口腔生物科學研究所
94
Enterovirus 71 has been the most important enterovirus to cause hand-foot-and-mouth disease accompanied with neurological complication. EV71, like the poliovirus, belongs to the Picornaviridae family and there are four kinds of structural proteins, VP1-VP4, to assemble the virions. It is generally considered that VP1 is the most important antigenic determinant of EV71. Therefore, previous studies on the EV71 vaccine most focused on the inactivated virus and VP1, but inactivated virus vaccine had better protection than VP1 subunit vaccine. In addition, studies on poliovirus showed that three to four neutralizing antigenic sites have been described, involving residues of all three major structural proteins, VP1-VP3. Based on the reasons above, we want to identify neutralizing epitopes of EV71 Caspid, other than VP1, to improve vaccine. We purified other recombinant caspid proteins, other than VP1, to immunize BALB/c mice accompanied with CFA/IFA or cholera toxin as adjuvant. We demonstrated the VP0 (VP0 is the propeptide of VP2 and VP4) and VP3 can induce specific antibodies. In the neutralization test, we also found that anti-VP0 and anti-VP3 serum can protect RD cell against virus infection as well as anti-VP1 serum. Further, serum samples from EV71-immunized mice had the best neutralization effect. About the antigen saturation study, only inactivated virus could block neutralization effect of anti-virus serum. We suggested that denatured VP1, VP3, and VP0 might lose most of conformational epitopes during the purification and had low affinity with anti-virus serum. In the other hand, we estimated the component of anti-virus serum by ELISA and we found that VP1-specific antibody was more than VP3 and VP4-specific antibody. Then, we combined different structural proteins with different ratio to immunize BALB/c mice via nasal route for the reason that induction of mucosal immunity to protect virus infection in the first line of defense. The results showed that only inactivated virus can elicit great magnitude of immune response. In conclusion, antibodies induced by EV71 capsid proteins, other than VP1, had neutralization effect and whole virus could induce the best neutralizing antibodies and mucosal immunity. We estimated components of anti-virus serum by ELISA and considered that VP1 might be more important neutralizing epitopes in virus infection. We considered that intact virus is the proper candidate of the EV71 vaccine development. Thus, we will design enterovirus-like particle for development of mucosal vaccine.
Meniaï, Ilhem. "Utilisation de la vaccinologie réverse pour l’identification de protéines candidates vaccinales chez Clostridium perfringens causant l’entérite nécrotique aviaire." Thesis, 2020. http://hdl.handle.net/1866/24261.
Повний текст джерелаAvian necrotic enteritis caused by Clostridium perfringens is a disease with a major economical impact, generating losses up to 6 billion dollars for the poultry industry worldwide. This disease appears in broiler chicken flocks that no longer employ the use of antibiotics. To date, no alternative method allows for the efficient prevention of necrotic enteritis (NE) and a control by a vaccinal strategy would be mostly prized. A comparative genomics approach as well as comparative and subtractive reverse vaccinology identifying immunogenic bacterial surface proteins is one of the most promising methodologies for the rapid development of an efficient vaccine. A comparative genomic study was performed on 48 C. perfringens strains isolated from healthy broiler chickens and from broilers affected by necrotic enteritis. From this study, it was established that the genomes analyzed were composed of 155 700 distinct proteins where 13% were predicted to have an extracellular expression, 65% at the cytoplasma level and 22% within the plasma membrane. The evaluation of the immunogenic potential of these proteins was established with the prediction software VaxiJen v2.0 for which a 0.5 threshold score allowed for the identification of four score categories among the identified proteins, from 0.5 to 1.5. For the most part, proteins with the highest scores were associated with an extracellular localisation. The combination of the immunogenicity score and localisation of the analysed proteins led to the selection of 12 vaccinal candidate proteins that were mostly identified as hypothetical. A more in-depth description of these proteins would allow the assessment of their function, the evaluation of their true immunogenic potential by characterizing their interaction with the avian immune system and ultimately, evaluate their probable role in the pathogenesis of necrotic enteritis.
Gomez, Gabriel. "Identification and Evaluation of Brucella Recombinant Outer Membrane Proteins as Subunit Vaccinogen Candidates in the Mouse Model of Brucellosis." Thesis, 2013. http://hdl.handle.net/1969.1/149282.
Повний текст джерелаTseng, Ta-Yuan, and 曾達元. "Producing the Recombinant Structural Protein of Chicken Anemia Virus and Chicken Interleukin-12 as Vaccine Candidates by Baculovirus Expression System." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/g32ef6.
Повний текст джерела國立中興大學
微生物暨公共衛生學研究所
106
Chicken anemia virus(CAV)is one of the important pathogens affecting poultry industry globally. The virus causes mortality, production losses, immunosuppression, sensitive to infections and vaccination failures in infected chickens. Currently, only live attenuated chicken infectious anemia(CIA)vaccines are available for administering in breeders older than 8 weeks that induce maternal antibodies to protect their progeny till 3 weeks. However, the vaccine viruses could induce vertical and horizontal infection to other chickens. These disadvantages of the traditional vaccines induce the idea to develop novel CIA vaccines. According to previous studies, VP1 is the only structural protein forming the viral capsid, and the correct folding of VP1 requires expression of VP1 and VP2 in the same cell. Interleukin-12(IL-12)is a proinflammatory cytokine, which is responsible for enhancing cytotoxicity of NK cells and T cells. Moreover, IL-12 facilitates the generation of related TH1 cytokines, and promotes the production of immunoglobulins by stimulating helper T cells. Therefore, IL-12 can be serve as a biological adjuvant. In this study, the baculovirus expression system was used to produce the structural protein of CAV and chicken IL-12(chIL-12)for developing a subunit vaccine candidate. The VP1 and VP2 of CAV and the chIL-12 gene codons were optimized for expressing in the insect cells, and the recombinant proteins were expressed by the baculovirus expression system. Western blot and indirect immunofluorescence assays were used to verify the expression of recombinant proteins. The results showed that VP1 and chIL-12 can be expressed in eukaryotic cells. We found that VP1 predominantly aggregated in the nucleus, and the amount of expression level needs to be further optimized. Biological adjuvant property of chIL-12 has been tested by inducing high expression level of IFN-γ in the recombinant chIL-12 stimulated splenocytes. Finally, different concentrations of recombinant VP1 and chIL-12 has been combined together to assess immune responses in chickens, and the results showed that VP1 combined with chIL-12 achieved the highest titers of CAV specific antibody than those of other groups. Taken together, the recombinant VP1 could be a candidate of CAV subunit vaccine, and co-immunization of chIL-12 can induce a strong immune response in vaccinated chickens.
Kitowski, Annabel Katharina. "Bio-orthogonal site-selective labelling of carbohydrates and proteins." Doctoral thesis, 2019. http://hdl.handle.net/10451/44169.
Повний текст джерела